Shanghai HepaBiotech
Shanghai HepaBiotech is dedicated to the development and application of advanced 3D microtissue platforms, delivering robust safety, efficacy, and metabolic evaluations to support preclinical drug development. Our founding team originates from the Karolinska Institute, home to the Nobel Assembly for the Nobel Prize in Physiology or Medicine. We have partnered with more than sixty leading pharmaceutical companies worldwide, providing industry-trusted preclinical evaluation solutions that accelerate innovative drug development.
Luna LifeSci Advisors
Luna LifeSci Advisors consults across the NAMs ecosystem, helping MPS developers grow and scale novel platforms, and guiding pharma and CROs to evaluate, adopt, and integrate MPS technologies into preclinical workflows. Our 25+ years of expertise spans strategy, technology development, platform validation, workflow integration, regulatory alignment, fundraising, company building, and commercial execution.
TheWell Bioscience
TheWell Bioscience provides xeno-free, 3D cell culture solutions, empowering research in organoids, regenerative medicine, and drug discovery.
Dynamic42 GmbH
Dynamic42 has developed a PDMS-free, easy-to-handle, affordable OoC platform. We specialize in vascular, liver, lung and intestinal biology and infection models. We further enable scientists with training courses to establish their own OoC models.
STEMCELL Technologies
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.
Hesperos Inc.
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
CN Bio
CN Bio is a leading bioengineering company specializing in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of tomorrow’s medicines.
MIMETAS
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.